Boston's Tufts Medical Center awards Jonathan Bush for visionary leadership

Tufts Medical Center will award the Ellen M. Zane Award for Visionary Leadership to athenahealth Chairman and CEO Jonathan Bush.

As the recipient of the award, Bush is being honored for exemplifying visionary and transformational leadership in the community, according to the organization. Tufts cites Bush's "passion for uniting individualized and coordinated patient care with the demands and practicalities of healthcare management. His innovative work has transformed how the healthcare industry operates, from patients to healthcare providers nationwide."

Bush co-founded athenahealth in 1997 and took it public in 2007 in the most successful initial public offering that year. Bush's background includes serving as an emergency medical technician for the City of New Orleans, training as a medic in the U.S. Army and working as a management consultant in the healthcare practice of Booz Allen & Hamilton. He obtained a Bachelor of Arts in the College of Social Studies from Wesleyan University and an MBA from Harvard Business School. Bush currently serves on the Harvard Medical School Board of Fellows.

The award will be presented to Bush at the 2016 Working Wonders for Tufts Medical Center benefit event on March 16 in Boston.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.